(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 24.84% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.31%, and while it is forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Valneva Se's revenue in 2026 is $206,796,551.On average, 8 Wall Street analysts forecast VALN's revenue for 2026 to be $32,032,848,095, with the lowest VALN revenue forecast at $27,612,396,256, and the highest VALN revenue forecast at $40,105,613,006. On average, 7 Wall Street analysts forecast VALN's revenue for 2027 to be $63,097,808,865, with the lowest VALN revenue forecast at $51,928,129,312, and the highest VALN revenue forecast at $72,658,132,147.
In 2028, VALN is forecast to generate $55,000,684,373 in revenue, with the lowest revenue forecast at $37,249,046,223 and the highest revenue forecast at $77,176,022,306.